[go: up one dir, main page]

AR077435A1 - Composiciones dermatologicas de antagonistas del receptor dp2 y uso - Google Patents

Composiciones dermatologicas de antagonistas del receptor dp2 y uso

Info

Publication number
AR077435A1
AR077435A1 ARP100102809A ARP100102809A AR077435A1 AR 077435 A1 AR077435 A1 AR 077435A1 AR P100102809 A ARP100102809 A AR P100102809A AR P100102809 A ARP100102809 A AR P100102809A AR 077435 A1 AR077435 A1 AR 077435A1
Authority
AR
Argentina
Prior art keywords
substituted
alkyl
unsubstituted
unsubstituted phenyl
fluoroalkyl
Prior art date
Application number
ARP100102809A
Other languages
English (en)
Inventor
John Howard Hutchinson
Original Assignee
Amira Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amira Pharmaceuticals Inc filed Critical Amira Pharmaceuticals Inc
Publication of AR077435A1 publication Critical patent/AR077435A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicacion 1: Se reivindica una composicion de uso topico que incluye un antagonista del receptor DP2 y al menos un excipiente farmacéuticamente aceptable y que constituye un ungüento, una crema, una locion, una pasta, un gel, una barra, una película, un parche o un vendaje, composicion de uso topico ésta que puede ser administrada a la piel de un mamífero. Reivindicacion 2: La composicion de uso topico de la reivindicacion 1, donde el antagonista de DP2 es un compuesto que se rige por la estructura de la formula (1) o una sal o solvato farmacéuticamente aceptable o una prodroga del mismo, donde, R4 es H, halogeno, -CN, -OH, alquilo C1-4, alcoxi C1-4, fluoroalquilo C1-4, fluoroalcoxi C1-4 o heteroalquilo C1-4; R5 es H, halogeno, -CN, -NO2, -OH, -OR13, -SR12, -S(=O)R12, -S(=O)2R12, -NHS(=O)2R12, -C(=O)R12, -OC(=O)R12, -CO2R13, -OCO2R13, -CH(R13)2, -N(R13)2, -C(=O)N(R13)2, -OC(=O)N(R13)2, -NHC(=O)NH(R13), -NHC(=O)R12, -NHC(=O)OR12, -C(OH)(R13)2, alquilo C1-6, fluoroalquilo C1-6, fluoroalcoxi C1-6, alcoxi C1-6 o heteroalquilo C1-6; o R5 es cicloalquilo C3-10, un heterocicloalquilo C2-10 sustituido o insustituido, un fenilo sustituido o insustituido, un naftilo sustituido o insustituido, un heteroarilo monocíclico sustituido o insustituido o un heteroarilo bicíclico sustituido o insustituido donde, si R5 es sustituido, el mismo es sustituido con 1 o 2 grupos R21; R20 es alquilo C1-4, cicloalquilo C3-6, -CH2O-alquilo C1-4, -CH2O-(fenilo sustituido o insustituido), -CH(CH3)-O-(fenilo sustituido o insustituido), -C(CH3)2-O-(fenilo sustituido o insustituido), -CH2OCH2-(fenilo sustituido o insustituido), -O-alquilo C1-4, -O-CH2-(fenilo sustituido o insustituido), -OCH(CH3)-(fenilo sustituido o insustituido), -NR16-alquilo C1-4, -NR16-CH2-(fenilo sustituido o insustituido) o -NR16-CH(CH3)-(fenilo sustituido o insustituido) donde, si el fenilo de R20 es sustituido, este ultimo es sustituido con 1 o 2 grupos R21; cada R21 es seleccionado de manera independiente a partir de halogeno, -OH, -O-alquilo C1-4, alquilo C1-4 y -CF3; R16 es H o alquilo C1-4; R11 es alquilo C1-4, fluoroalquilo C1-4 o cicloalquilo C3-6; R12 es alquilo C1-4, heteroalquilo C1-4 o fluoroalquilo C1-4; cada R13 es seleccionado de manera independiente a partir de H, alquilo C1-4, heteroalquilo C1-4 y fluoroalquilo C1-4. Reivindicacion 4: La composicion de uso topico de cualquiera de las reivindicaciones 1-3, composicion de uso topico ésta que es utilizada en el tratamiento de una enfermedad o condicion dermatologica dependiente de la prostaglandina D2 o mediada por la prostaglandina D2 en un mamífero. Reivindicacion 21: El uso de cualquiera de las reivindicaciones 12-20, el cual adicionalmente incluye un segundo agente terapéutico. Reivindicacion 22: El uso de la reivindicacion 21, donde el segundo agente terapéutico es un antibiotico, un agente antimicotico, un agente antiinflamatorio esteroideo, un agente antiinflamatorio no esteroideo, un antihistamínico, un agente antiviral, un agente estabilizador de los mastocitos, una ciclosporina o un modulador de los leucotrienos.
ARP100102809A 2009-07-31 2010-07-30 Composiciones dermatologicas de antagonistas del receptor dp2 y uso AR077435A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23058509P 2009-07-31 2009-07-31

Publications (1)

Publication Number Publication Date
AR077435A1 true AR077435A1 (es) 2011-08-24

Family

ID=43503080

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102809A AR077435A1 (es) 2009-07-31 2010-07-30 Composiciones dermatologicas de antagonistas del receptor dp2 y uso

Country Status (11)

Country Link
US (1) US20120184493A1 (es)
EP (1) EP2480225A4 (es)
JP (1) JP2013500979A (es)
KR (1) KR20120046762A (es)
CN (1) CN102596193A (es)
AR (1) AR077435A1 (es)
CA (1) CA2768586A1 (es)
SG (1) SG177736A1 (es)
TW (1) TWI428315B (es)
UY (1) UY32820A (es)
WO (1) WO2011014588A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2618352T3 (es) 2006-06-16 2017-06-21 The Trustees Of The University Of Pennsylvania Antagonistas del receptor de prostaglandina D2 para el tratamiento de la alopecia androgenética
US20150072963A1 (en) * 2006-06-16 2015-03-12 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating hair growth
CN101903338A (zh) 2007-12-19 2010-12-01 安姆根有限公司 用作炎症调节剂的苯基乙酸衍生物
US8067445B2 (en) 2008-02-01 2011-11-29 Panmira Pharmaceuticals, Llc N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
US8242145B2 (en) 2008-02-14 2012-08-14 Panmira Pharmaceuticals, Llc Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
JP2011513242A (ja) 2008-02-25 2011-04-28 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体アンタゴニスト
JP2011518130A (ja) 2008-04-02 2011-06-23 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体のアミノアルキルフェニルアンタゴニスト
WO2010008864A2 (en) 2008-06-24 2010-01-21 Amira Pharmaceuticals, Inc. Cycloalkane[b]indole angtagonists of prostaglandin d2 receptors
MX2010014172A (es) 2008-07-03 2011-02-22 Amira Pharmaceuticals Inc Antagonistas de receptores de prostaglandina d2.
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
US8378107B2 (en) 2008-10-01 2013-02-19 Panmira Pharmaceuticals, Llc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
WO2011014587A2 (en) 2009-07-31 2011-02-03 Amira Pharmaceuticals, Inc. Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
KR20120047273A (ko) 2009-08-05 2012-05-11 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 길항제 및 이의 용도
AU2011203649A1 (en) 2010-01-06 2012-06-14 Brickell Biotech, Inc. DP2 antagonist and uses thereof
ES2553871T3 (es) 2010-07-05 2015-12-14 Actelion Pharmaceuticals Ltd. Derivados heterociclilo 1-fenil-sustituidos y su uso como moduladores del receptor D2 de prostaglandina
WO2013093842A1 (en) 2011-12-21 2013-06-27 Actelion Pharmaceuticals Ltd Heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
EA033143B1 (ru) * 2012-03-21 2019-09-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Способ и применение селективного антагониста dp-2 по отношению к dp-1 для стимулирования роста волос
JP6127135B2 (ja) 2012-07-05 2017-05-10 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ １−フェニル置換ヘテロシクリル誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用
FR3000399B1 (fr) * 2012-12-31 2015-03-27 Galderma Res & Dev Utilisation topique du laropiprant pour le traitement de la rosacee
WO2014159771A1 (en) 2013-03-13 2014-10-02 The Regents Of The University Of California Prevention of rosacea inflammation
EA030159B1 (ru) * 2014-03-17 2018-06-29 Идорсиа Фармасьютиклз Лтд Производные азаиндолуксусной кислоты и их применение в качестве модуляторов рецепторов простагландина d2
US20180021302A1 (en) * 2015-02-13 2018-01-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
RU2630775C2 (ru) * 2015-11-13 2017-09-13 Федеральное государственное унитарное предприятие "Институт химических реактивов и особо чистых химических веществ Национального исследовательского центра "Курчатовский институт" 2-арил-1,3-тиазолидин-4-карбоновые кислоты, обладающие противоопухолевой активностью
JP7122499B2 (ja) * 2016-06-03 2022-08-22 幸久 村田 がん転移阻害剤
KR20210008223A (ko) 2019-07-11 2021-01-21 제이투에이치바이오텍 (주) 탈모증의 치료 또는 개선을 위한 화합물 및 이들의 용도
WO2025104233A1 (en) * 2023-11-16 2025-05-22 Vib Vzw Inhibition of prostaglandin d2 receptor 1 as means for treating cancer
WO2025104238A1 (en) * 2023-11-16 2025-05-22 Vib Vzw Inhibition of prostaglandin d2 receptor 2 as means for treating cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004182657A (ja) * 2002-12-04 2004-07-02 Eisai Co Ltd Ｈｄｌレベル上昇促進剤
BR0317591A (pt) * 2002-12-20 2005-11-22 Amgen Inc Composto, sal ou pró-medicamento farmaceuticamente aceitáveis, composição farmacêutica, e, métodos para tratar uma doença ou condição, para modular a função de crth2 e/ou um ou mais outros receptores de pgd2 em uma célula e para modular crth2 e/ou um ou mais outros receptores de pgd2
GB0324763D0 (en) * 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
ES2304010T3 (es) * 2004-03-11 2008-09-01 Actelion Pharmaceuticals Ltd. Derivados de tetrahidropiridoindol.
US7405302B2 (en) * 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
JP2009539881A (ja) * 2006-06-09 2009-11-19 アイコス コーポレイション Ｄｐ−２アンタゴニストとしての置換フェニル酢酸
US8067445B2 (en) * 2008-02-01 2011-11-29 Panmira Pharmaceuticals, Llc N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors

Also Published As

Publication number Publication date
CN102596193A (zh) 2012-07-18
JP2013500979A (ja) 2013-01-10
UY32820A (es) 2011-01-31
TW201107293A (en) 2011-03-01
US20120184493A1 (en) 2012-07-19
TWI428315B (zh) 2014-03-01
KR20120046762A (ko) 2012-05-10
EP2480225A4 (en) 2013-05-01
WO2011014588A2 (en) 2011-02-03
SG177736A1 (en) 2012-02-28
WO2011014588A3 (en) 2011-06-23
EP2480225A2 (en) 2012-08-01
CA2768586A1 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
AR077435A1 (es) Composiciones dermatologicas de antagonistas del receptor dp2 y uso
ES2652595T3 (es) Lactonas de sesquiterpeno tricíclico para el uso en el tratamiento de la obesidad y enfermedades relacionadas y condiciones tratables no terapéuticas
AR077516A1 (es) Composiciones farmaceuticas de uso oftalmico de antagonistas del receptor dp2. uso. compuesto.
US11224599B2 (en) Therapeutic agents and methods
UY32833A (es) Antagonistas dp2 y usos del mismo
AR060631A1 (es) Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k)
CA2904794A1 (en) Modulators of the eif2alpha pathway
RU2013142448A (ru) Новые сульфонаминохинолиновые антагонисты гепсидина
AR069490A1 (es) Agonistas de los receptores de glucocorticoides
JP2016519078A5 (es)
RU2013152788A (ru) Амидные соединения и их фармацевтическое применение
UA109688C2 (xx) Трициклічні інгібітори pі3k та їх застосування
AR064561A1 (es) Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina.
EA201070929A1 (ru) ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ
EA201390840A1 (ru) Полициклический lpaантагонист и его применение
JP2011516460A5 (es)
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
US11702443B2 (en) Therapeutic agents and methods
CL2010001528A1 (es) Compuestos derivados del acido 7-fenoxicroman-4-carboxilico sustituido; proceso de preparacion; compuesto intermediario; composicion farmaceutica de dicho compuesto; y su uso como antagonista de los receptores de prostaglandina d2 (pgd2) para tratar trastornos inmunologicos, enfermedades alergicas, trastornos inflamatorios.
CA3162069A1 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
WO2014178789A9 (en) Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients
AU2025213600A1 (en) Nurr1 receptor modulators
NO20092764L (no) Isosorbid mononitrat derivater for behandling av okular hypertensjon
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl
JP2013539779A (ja) 化合物

Legal Events

Date Code Title Description
FA Abandonment or withdrawal